Creating a Clinical Diagnostic Test from Discovery Through Launch with Mass Spectrometry

Video   Apr 14, 2015

 

Recently, we evaluated the performance of 190 candidate protein biomarkers to discriminate between patients with benign or malignant lung nodules.  The candidate markers came from the substantial literature on cancer-associated proteins as well as from mass spectrometry studies, conducted in-house to identify proteins up-regulated either on the surface of tumors or in the secretome of tumors, as compared to adjacent normal lung tissue. Plasma samples were obtained retrospectively for analysis from those with either benign or malignant nodules.  A 13 protein panel was identified with a high negative predictive value, able to remove approximately half of those with benign nodules from further consideration.  The test has been commercialized, using MRM mass spectrometry, by Integrated Diagnostics.

 
 
 
 

Recommended Videos

Behind the Science, S2 Ep6: Dimple Shah on detecting phthalates in whisky

Video

Got phthalates? We hope not. Jen talks with senior scientist Dimple Shah about how these potential endocrine disruptors are found in food and beverages such as distilled beverages and whisky

WATCH NOW

The Evolution of PCR

Video

Launching the first FDA-approved PCR test in 1993, Roche Molecular Diagnostics has not only defined and refined PCR, but it has remained the clear leader of this technology.

WATCH NOW

DeNovix DS-11 FX Spectrophotometer / Fluorometer Series: 1uL UV-Vis + Fluorescence

Video

The DeNovix DS-11 FX Series of Spectrophotometers / Fluorometers combine UV-Vis absorbance and fluorescence methods in one compact , maintenance-free instrument. Rapidly quantify nucleic acids and protein samples selecting your choice of UV-Vis or Fluorescent modes.

WATCH NOW

 

Comments | 0 ADD COMMENT

Like what you just watched? You can find similar content on the communities below.

Analysis & Separations Diagnostics Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE